(Q33392364)

English

Trabectedin in pre-treated patients with advanced or metastatic soft tissue sarcoma: a phase II study evaluating co-treatment with dexamethasone

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Trabectedin in pre-treated patients with advanced or metastatic soft tissue sarcoma: a phase II study evaluating co-treatment with dexamethasone (English)

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

1 reference

based on heuristic

inferred from title

object named as

Eva Ciruelos

5

0 references

Mariano Provencio

object named as

Mariano Provencio

8

0 references

author name string

Luis Paz-Ares

1

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Antonio López-Pousa

2

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Andrés Poveda

3

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Carmen Balañá

4

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Joaquim Bellmunt

6

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Javier García del Muro

7

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Antonio Casado

9

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Fernando Rivera-Herrero

10

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Miguel Angel Izquierdo

11

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Antonio Nieto

12

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Adnan Tanović

13

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Hernán Cortes-Funes

14

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

José María Buesa

15

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

publication date

20 October 2010

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Investigational New Drugs

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

30

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

2

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

729-740

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Soft-tissue sarcomas in adults

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9561-9

21 January 2018

Doxorubicin versus CYVADIC versus doxorubicin plus ifosfamide in first-line treatment of advanced soft tissue sarcomas: a randomized study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9561-9

21 January 2018

Results of randomised studies of the EORTC Soft Tissue and Bone Sarcoma Group (STBSG) with two different ifosfamide regimens in first- and second-line chemotherapy in advanced soft tissue sarcoma patients

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9561-9

21 January 2018

Unique features of the mode of action of ET-743.

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9561-9

21 January 2018

Antiproliferative activity of ecteinascidin 743 is dependent upon transcription-coupled nucleotide-excision repair.

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9561-9

21 January 2018

In vitro antitumor activity of the novel marine agent, ecteinascidin-743 (ET-743, NSC-648766) against human tumors explanted from patients

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9561-9

21 January 2018

High antitumour activity of ET743 against human tumour xenografts from melanoma, non-small-cell lung and ovarian cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9561-9

21 January 2018

Phase I and pharmacokinetic study of Yondelis (Ecteinascidin-743; ET-743) administered as an infusion over 1 h or 3 h every 21 days in patients with solid tumours

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9561-9

21 January 2018

Phase I and pharmacokinetic study of ecteinascidin-743, a new marine compound, administered as a 24-hour continuous infusion in patients with solid tumors.

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9561-9

21 January 2018

Clinical pharmacology of the novel marine-derived anticancer agent Ecteinascidin 743 administered as a 1- and 3-h infusion in a phase I study

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9561-9

21 January 2018

Phase II study of ecteinascidin-743 in advanced pretreated soft tissue sarcoma patients

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9561-9

21 January 2018

Phase II and pharmacokinetic study of ecteinascidin 743 in patients with progressive sarcomas of soft tissues refractory to chemotherapy.

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9561-9

21 January 2018

Phase II study of ET-743 in advanced soft tissue sarcomas: a European Organisation for the Research and Treatment of Cancer (EORTC) soft tissue and bone sarcoma group trial

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9561-9

21 January 2018

Ecteinascidin-743 (ET-743) for chemotherapy-naive patients with advanced soft tissue sarcomas: multicenter phase II and pharmacokinetic study

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9561-9

21 January 2018

Efficacy and safety of trabectedin in patients with advanced or metastatic liposarcoma or leiomyosarcoma after failure of prior anthracyclines and ifosfamide: results of a randomized phase II study of two different schedules

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9561-9

21 January 2018

Reporting results of cancer treatment

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9561-9

21 January 2018

Optimal two-stage designs for phase II clinical trials

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9561-9

21 January 2018

Imaging and response in soft tissue sarcomas

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9561-9

21 January 2018

Doxorubicin (or epidoxorubicin) combined with ifosfamide in the treatment of adult advanced soft tissue sarcomas

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9561-9

21 January 2018

Trabectedin for women with ovarian carcinoma after treatment with platinum and taxanes fails.

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9561-9

21 January 2018

Pharmacokinetics of ecteinascidin 743 administered as a 24-h continuous intravenous infusion to adult patients with soft tissue sarcomas: associations with clinical characteristics, pathophysiological variables and toxicity

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9561-9

21 January 2018

Steroid premedication markedly reduces liver and bone marrow toxicity of trabectedin in advanced sarcoma.

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9561-9

21 January 2018

Modulation of trabectedin (ET-743) hepatobiliary disposition by multidrug resistance-associated proteins (Mrps) may prevent hepatotoxicity

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9561-9

21 January 2018

Semimechanistic pharmacokinetic/pharmacodynamic model for hepatoprotective effect of dexamethasone on transient transaminitis after trabectedin (ET-743) treatment

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9561-9

21 January 2018

Population pharmacokinetic meta-analysis of trabectedin (ET-743, Yondelis) in cancer patients.

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9561-9

21 January 2018

Randomized Phase II Study of Docetaxel Versus Doxorubicin in First- and Second-Line Chemotherapy for Locally Advanced or Metastatic Soft Tissue Sarcomas in Adults: A Study of the European Organization for Research and Treatment of Cancer Soft Tissue

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9561-9

21 January 2018

Rat and human liver cytochrome P-450 isoform metabolism of ecteinascidin 743 does not predict gender-dependent toxicity in humans

1 reference

https://pubmed.ncbi.nlm.nih.gov/20960029

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Complete protection by high-dose dexamethasone against the hepatotoxicity of the novel antitumor drug yondelis (ET-743) in the rat

1 reference

https://pubmed.ncbi.nlm.nih.gov/20960029

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

New drugs for the treatment of sarcomas.

1 reference

https://pubmed.ncbi.nlm.nih.gov/20960029

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase I and pharmacokinetic study of ecteinascidin 743 administered as a 72-hour continuous intravenous infusion in patients with solid malignancies

1 reference

https://pubmed.ncbi.nlm.nih.gov/20960029

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Progression-free rate as the principal end-point for phase II trials in soft-tissue sarcomas

1 reference

https://pubmed.ncbi.nlm.nih.gov/20960029

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Trabectedin: a review of its use in soft tissue sarcoma and ovarian cancer.

1 reference

https://pubmed.ncbi.nlm.nih.gov/20960029

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A phase I and pharmacokinetic study of ecteinascidin-743 on a daily x 5 schedule in patients with solid malignancies

1 reference

https://pubmed.ncbi.nlm.nih.gov/20960029

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S10637-010-9561-9

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Dimensions Publication ID

0 references

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q33392364&oldid=2195315750"